Stock TCRX TSCAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
5.85 USD -6.25% Intraday chart for TScan Therapeutics, Inc. -10.00% +0.34%
06-17 Certain Pre-Funded Warrants of TScan Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2024. CI
06-17 Certain Stock Options of TScan Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 17-JUN-2024. CI

Evolution of the average Target Price on TScan Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

da.QToz9eMtpPtbPzCX4c8YOkpnOFHhpZCLa-M8Vgt7a44.BghDndQe9bwTXgHirfhyQwVeXRmI8Kn5EdRoY0McWc0rdkOQuRqJtR5pfQ~1eb49ed2d7ebc813b9eb138373a4aa0e

Analyst Recommendations on TScan Therapeutics, Inc.

Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target MT
Barclays Raises Price Target on TScan Therapeutics to $9 From $7, Keeps Overweight Rating MT
Wedbush Adjusts TScan Therapeutics Price Target to $10 From $9, Maintains Outperform Rating MT
Wedbush Lifts TScan Therapeutics' Price Target to $9 From $8, Keeps Outperform Rating MT
Wedbush Starts TScan Therapeutics at Outperform With $8 Price Target, Notes Cadence of Near-Term Catalysts, Differentiated Technology Capabilities MT
HC Wainwright Lowers TScan Therapeutics Price Target to $15 From $21, Maintains Buy Rating MT
HC Wainwright Starts TScan Therapeutics at Buy With $21 Price Target MT
TSCAN THERAPEUTICS : Cowen Initiates Coverage on TScan Therapeutics With Outperform Rating MT
TSCAN THERAPEUTICS : Barclays Starts TScan Therapeutics at Overweight with $22 Price Target MT
TSCAN THERAPEUTICS : Jefferies Starts Tscan Therapeutics at Buy With $21 Price Target MT
TSCAN THERAPEUTICS : Morgan Stanley Starts TScan Therapeutics at Overweight With $22 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
5.85 USD
Average target price
12.29 USD
Spread / Average Target
+110.01%
High Price Target
15 USD
Spread / Highest target
+156.41%
Low Price Target
10 USD
Spread / Lowest Target
+70.94%

Consensus detail

Consensus revision (last 18 months)

Analysts covering TScan Therapeutics, Inc.

Janney Capital
Barclays
Wedbush
HC Wainwright
Cowen
Jefferies & Co.
Morgan Stanley

Ratings for TScan Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TCRX Stock
  4. Consensus TScan Therapeutics, Inc.